Key facts
- It has raised $165.0M across 4 recorded rounds; the latest was Later Stage VC (Series C) ($75.0M) in Jun 2020.
- 4D Molecular Therapeutics has filed 3 Form Ds with the SEC since 2015, most recently Sep 2018 ($90.0M sold to 31 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for 4D Molecular Therapeutics
Create free account
No card required
Funding rounds
4 roundsJun 2020Later Stage VC (Series C)$75.0M▮
Sep 2018Early Stage VC (Series B)$90.0M▮
About 4D Molecular Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
4D Molecular Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in 4D Molecular Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on 4D Molecular Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.